Söndag 1 Juni | 06:44:30 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-10-08 08:20 Bokslutskommuniké 2025
2025-06-25 08:20 Kvartalsrapport 2025-Q3
2025-05-09 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2025-04-09 - Kvartalsrapport 2025-Q2
2025-01-29 - Kvartalsrapport 2025-Q1
2024-12-05 - Årsstämma
2024-10-09 - Bokslutskommuniké 2024
2024-06-26 - Kvartalsrapport 2024-Q3
2024-05-08 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2024-03-27 - Kvartalsrapport 2024-Q2
2024-01-24 - Kvartalsrapport 2024-Q1
2023-12-01 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2023-11-30 - Årsstämma
2023-10-11 - Bokslutskommuniké 2023
2023-10-10 - Extra Bolagsstämma 2023
2023-06-28 - Kvartalsrapport 2023-Q3
2023-04-05 - Kvartalsrapport 2023-Q2
2023-01-25 - Kvartalsrapport 2023-Q1
2022-12-02 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2022-12-01 - Årsstämma
2022-10-05 - Bokslutskommuniké 2022
2022-06-22 - Kvartalsrapport 2022-Q3
2022-03-30 - Kvartalsrapport 2022-Q2
2022-01-26 - Kvartalsrapport 2022-Q1
2021-12-03 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2021-12-02 - Årsstämma
2021-10-13 - Bokslutskommuniké 2021
2021-06-23 - Kvartalsrapport 2021-Q3
2021-03-25 - Kvartalsrapport 2021-Q2
2021-01-20 - Kvartalsrapport 2021-Q1
2020-11-27 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2020-11-26 - Årsstämma
2020-10-07 - Bokslutskommuniké 2020
2020-06-24 - Kvartalsrapport 2020-Q3
2020-03-25 - Kvartalsrapport 2020-Q2
2020-01-22 - Kvartalsrapport 2020-Q1
2019-11-22 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2019-11-21 - Årsstämma
2019-10-02 - Bokslutskommuniké 2019
2019-06-26 - Kvartalsrapport 2019-Q3
2019-03-27 - Kvartalsrapport 2019-Q2
2019-01-23 - Kvartalsrapport 2019-Q1
2018-11-16 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2018-11-15 - Årsstämma
2018-10-03 - Bokslutskommuniké 2018
2018-06-27 - Kvartalsrapport 2018-Q3
2018-03-28 - Kvartalsrapport 2018-Q2
2018-01-24 - Kvartalsrapport 2018-Q1
2017-11-30 - Årsstämma
2017-10-31 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2017-10-11 - Bokslutskommuniké 2017
2017-06-28 - Kvartalsrapport 2017-Q3
2017-04-05 - Kvartalsrapport 2017-Q2
2017-02-22 - Kapitalmarknadsdag 2017
2017-01-25 - Kvartalsrapport 2017-Q1
2016-11-25 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2016-11-24 - Årsstämma
2016-10-12 - Bokslutskommuniké 2016
2016-06-29 - Kvartalsrapport 2016-Q3
2016-04-06 - Kvartalsrapport 2016-Q2
2016-01-20 - Kvartalsrapport 2016-Q1
2015-11-27 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2015-11-26 - Årsstämma
2015-10-14 - Bokslutskommuniké 2015
2015-07-01 - Kvartalsrapport 2015-Q3
2015-04-01 - Kvartalsrapport 2015-Q2
2015-01-21 - Kvartalsrapport 2015-Q1
2014-11-28 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2014-11-27 - Årsstämma
2014-10-15 - Bokslutskommuniké 2014
2014-07-02 - Kvartalsrapport 2014-Q3
2014-04-09 - Kvartalsrapport 2014-Q2
2014-01-22 - Kvartalsrapport 2014-Q1
2013-11-25 - X-dag ordinarie utdelning DMYD B 0.00 SEK
2013-11-22 - Årsstämma
2013-11-08 - Bokslutskommuniké 2013
2013-07-03 - Kvartalsrapport 2013-Q3
2013-05-21 - 15-7 2013

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Diamyd Medical är verksamt inom diabetesforskning. Bolaget har för närvarande tagit fram vaccin som innehåller den aktiva ingrediensen och molekylen GAD, en substans som har potential i att vara en viktig del i förebyggandet av diabetesbehandlingar i framtiden. Bolaget innehar verksamhet på global nivå med störst närvaro inom Norden. Huvudkontoret ligger i Stockholm.
2025-05-15 15:10:00

Following the announcement of the final outcome of Diamyd Medical AB's (publ) ("Diamyd Medical" or the "Company") rights issue carried out in April 2025, it has come to the Company's attention that, due to administrative reasons, one subscription application was not included in the final outcome. As a result, an adjustment has been necessary. After this adjustment, the number of subscribed A-units in the rights issue amounts to 514,624 and the number of subscribed B-units amounts to 27,686,603. Consequently, this means that the number of B-units issued within the framework of the additional unit issue included in the rights issue amounts to 2,409,103. Through the rights issue, the additional unit issue, and the directed issue carried out on May 5, 2025, the Company will thus receive approximately SEK 267 million before issue costs, adjusted from the previously communicated amount of approximately SEK 266 million.

Following the registration of the rights issue, the additional unit issue, and the directed issue, the Company's share capital will amount to SEK 13,945,395.1198, comprised of 137,499,723 shares, of which 3,503,120 are A-shares and 133,996,603 are B-shares.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. An early read-out of the Phase 3 trial is expected in March 2026. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group - both in a largescale meta-analysis as well as in the Company's prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.